Cadence Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Cadence Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,635	Closed	-$621K	–	659
2017 Q1	$621K	Buy	+10,635	New	+$510K	0.04%	467
2016 Q4	–	Sell	-13,290	Closed	-$702K	–	662
2016 Q3	$702K	Buy	+13,290	New	+$579K	0.05%	408
2015 Q3	–	Sell	-28,580	Closed	-$3.18M	–	593
2015 Q2	$3.18M	Sell	28,580 -2,120	-7%	-$228K	0.18%	148
2015 Q1	$2.9M	Sell	30,700 -8,320	-21%	-$932K	0.18%	159
2014 Q4	$4.37M	Buy	39,020 +34,400	+745%	+$3.07M	0.25%	112
2014 Q3	$283K	Buy	+4,620	New	+$199K	0.01%	519

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cadence Capital Management's AGIO Position: Q2 2017 in Review

Cadence Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2017, closing a stake of 10,635 shares — an estimated $621K sold.

Cadence Capital Management first reported a position in AGIO in Q3 2014 and held it in 6 quarters. The position peaked at $4.37M in Q4 2014. 167 funds tracked by Wall St. Rank hold AGIO as of Q2 2017.

Cadence Capital Management reported no remaining Agios Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Cadence Capital Management sold 10,635 Agios Pharmaceuticals shares in Q2 2017, an estimated $621K.
Cadence Capital Management first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Cadence Capital Management's Agios Pharmaceuticals position peaked at $4.37M in Q4 2014.
167 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2017.

Based on Cadence Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.